Articles tagged with: MLN9708
Takeda Oncology yesterday announced positive results from a key trial testing the investigational drug ixazomib in relapsed multiple myeloma patients.
Participants in the large Phase 3 ixazomib trial, known as the TOURMALINE MM-1 study, received one of two possible treatment regimens. One group was treated with ixazomib, Revlimid (lenalidomide), and dexamethasone (Decadron), while the other group received a placebo (sugar pill), Revlimid, and dexamethasone.
Investigators conducting the trial recently carried out the first planned interim analysis of the study results. Their analysis, Takeda reported …
A new year is upon us. I hope it has started well for everybody, and that all had a great holiday season!
The last few weeks of 2014 were a happening time for the multiple myeloma community. The short span of time witnessed the publication of updated criteria for the diagnosis of multiple myeloma from the International Myeloma Working Group (IMWG). In addition, the 56th annual meeting of the American Society of Hematology (ASH) took place in San Francisco, with literally hundreds of myeloma-related oral and poster presentations.
Therefore, it …
The 2014 annual meeting of the American Society of Hematology (ASH) starts tomorrow, December 5, in San Francisco, and will continue until next Tuesday.
The ASH annual meeting is one of several large medical conferences where myeloma-related research findings are presented each year. However, from a multiple myeloma perspective, the ASH meeting is generally the most important of the meetings.
At this year’s meeting, for example, some 500 myeloma-presentations are scheduled to take place. The presentations will summarize current research on a wide range of topics, including the biology of …
Monday was the third day of this year’s meeting of the American Society of Hematology (ASH). The day was filled with oral presentation sessions from early in the morning until into the evening.
In the afternoon and early evening, there were six oral presentation sessions devoted solely to multiple myeloma and a number of other myeloma-related presentations scattered about the afternoon. The topics of these presentations ranged from the biology of myeloma to treatment options for newly diagnosed, relapsed and refractory, and older patients.
This ASH update highlights most of …
This year’s meeting of the American Society of Hematology (ASH) began yesterday morning in New Orleans.
Myeloma-related presentations were made during several sessions yesterday.
Two sessions were designed to better educate physicians about multiple myeloma and how to treat the disease.
The key myeloma-related research presented yesterday was made public during a poster session in the evening about the biology of myeloma as well as preclinical and clinical studies testing new and existing treatments for myeloma.
During the session, research results were made available for review by meeting attendees in …